Our findings also highlight a decrease in TBK1 activity in MASH, observed in both mouse models and human samples, supporting the pathological relevance of TBK1 dysregulation in late stages of MASLD progression (Fig. 7H). Here, TBK1 is linked to metabolic dysfunction-associated steatotic liver disease.